The Evidence Was the Prescription, Not the Drug: Ruti Aga and the New Frontier of Anti-Doping Enforcement

Two years, plus four years, equals six.

Everything readable in the Ruti Aga case sits inside that sum. The rest — Ethiopian marathoner, thirty-two years old, a half marathon win in China in March, a knee injury — is context that the headline treated as decoration. The real question is not why her test came back positive. The real question is why she built a case in which two-thirds of the sanction was paid not for a drug, but for a piece of paper.

The Athletics Integrity Unit statement records two separate charges: presence of methylprednisolone, and tampering. Two years on the first, four on the second. Six in total, counted from 10 September — the same date her provisional suspension began. That backdating is not a discount; it is procedure. Provisional suspension time is credited against the ban. The real damage is not in the number. It is in the calendar. Add six years to thirty-two. The return age is thirty-eight.

Before anyone gets emotional about the word "steroid," a technical correction is necessary, because the original report got it wrong. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List. And the S9 condition matters: it is prohibited in-competition only, and only by injection, oral or rectal route. Which means a therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are present in-competition.

That is where the whole case has to be read from. The prosecution was never about the drug. It was about timing and route — and she had a legitimate defence available. She closed it herself.

I have spent thirteen years auditing transfer windows, and one lesson holds: when an institution asks you for documents and you do not have them, there are two paths — ask for time, or manufacture the paper. The first is expensive. The second is fatal. In road running that choice arrives in front of some athlete every month, and most of them have nobody around who understands it.

The medical governance vacuum

The detail in the AIU statement is not evidence of documentary fraud. It is evidence of a professional structure that was entirely absent. The prescription was written by a family member with no medical registration. That person claimed to have used "an old prescription pad from a former workplace." And the clinic named on the prescription did not exist. Three independent verification failures on a single sheet.

This is not a mistake. A mistake is a wrong date or a wrong dose. This is a system signal: the athlete had no credentialed team physician. If she had, one of two things would have happened — a Therapeutic Use Exemption application, or compliance with the S9 route-specific washout period. Neither happened. What happened was the third path: a forged document.

I built the screen to 2,900 names, then hunted the one that moved. That screen gave me a habit I still use — I count the attrition before I count the name. In this case the attrition count is one, but the reasons are three. Presence. Tampering. And a third that appears in no document: the absence of a support structure.

I have watched how that structure operates across Ethiopian and Kenyan road running for years. Altitude clubs, agent-run groups, and a training economy where a large share of athlete income comes from appearance fees rather than prize money. Appearance fees are paid for standing on the start line. If your knee hurts and you have to race in three weeks, the cheapest, most available and fastest solution is a glucocorticoid injection. This is standard sports medicine, especially in distance runners where knee synovitis is common.

That is why this is not one athlete's case. It is the case of a mechanism in which someone is always available to give the injection, and nobody is available to handle the paperwork.

The sanction arithmetic

Open the numbers, because the numbers are what tell you what the panel thought.

Two years for presence — consistent with the WADA Code position where the substance is Specified and intent is not proven. Four years for tampering — the Code's standard sanction, not an exceptional escalation. So the panel found the substance charge proven without aggravating intent, and treated the tampering as fully culpable.

There is a paradox here worth naming. A forged prescription is itself circumstantial evidence of concealment intent. Yet it did not escalate the presence sanction. The panel kept the two charges in separate boxes, as the Code requires. The result is that four of the six years attach to something with no proven performance benefit.

The disqualification scope nobody wrote down

The AIU statement does not specify which results were annulled. Standard practice is unambiguous: the competition at which the sample was collected is disqualified, along with its prize money. So the March half marathon in China — the win, the prize, the ranking points — goes.

What survives is the record before that date. The 2026 Tokyo Marathon title, and three second-place finishes at World Marathon Majors, belong to a period when no violation had been established. Absent a finding of earlier use, those results are not automatically voided. External records place her best at roughly 2:18:34 for second in Berlin 2026 and 2:20:40 for the Tokyo win in 2026 — those figures are not in the source report and remain pending verification, so read them as context, not evidence.

This is where the media narrative and the actual record diverge. The narrative says: a runner was caught. The record says: an athlete who won a Major and finished second at three others now has a career split into two halves — the titles, and the ban. Both are true. Both coexist.

A landscape the case does not move

Ethiopian women's marathon depth is such that removing a 2:18–2:20 performer changes nothing in national team arithmetic. That sounds harsh. It is a number. When the top end has reached sub-2:12 and an entire cohort sits below 2:16, the departure of a thirty-two-year-old with no global championship medal leaves no strategic hole.

Empty seats did not erase the sport; they exposed which metrics were merely crowd noise. When I pulled 892 behind-closed-doors matches in 2026, the lesson was that real change shows up where you do not expect it. In this case the change is not in competition. It is in enforcement.

What is genuinely shifting: anti-doping's frontier has moved from detection to document verification. The old question was whether the substance was present. The new question is whether your explanation can be verified. Aga's case is the cleanest example of that frontier, because the substance was minor and the paper was decisive.

China's label circuit: where appearance fees and testing meet on the same track

One point no report states but logic makes obvious: the March race in China was almost certainly a World Athletics Label road race, otherwise no AIU in-competition test would exist at all. And in road racing the testing window opens at 23:59 the day before the race — which means an injection given days earlier gets caught.

There is an economic contradiction worth understanding. Chinese and Asian label races are an attractive income tier for East African marathoners — large appearance fees, thinner fields than a Major, limited race count. That same tier is now the AIU's most productive testing ground. The appearance-fee economy and the testing economy are colliding in the same races. That collision will produce more cases.

The age curve, the cruellest number

Thirty-two. In women's marathon that is late peak meeting early decline. Six years later, thirty-eight. In the Ethiopian selection system, a thirty-eight-year-old with a doping record is effectively unselectable. That is not politics. It is arithmetic. The 2028 Olympic cycle is gone entirely.

What remains is commercial, not competitive. Distance-running sponsorship is already thin, and a sanctioned athlete becomes a brand liability.

Contrarian: six years for a drug with no proven benefit

Now the uncomfortable part, and I know it will not sit well.

State the consensus fairly first: the athlete submitted a forged document. That is serious. It is indefensible, and I am not softening it. Four years for tampering is the Code standard, and it is the standard because attacking the verification system is an attack on the entire regime.

But one fact stands. Glucocorticoids have no proven endurance performance benefit. They reduce inflammation, dull pain, and let an athlete do what they want to do despite the body's warning. That is medicine, not stimulation. A six-year, career-ending sanction has landed on what was technically a timing violation.

From here emerges the argument that keeps returning to athletics: is AIU enforcement disproportionate toward East African road runners? The honest answer is that I do not have the dataset. I had a 2,900-name screen. I do not have a classified dataset of every AIU case — which country, which substance, which sanction. Without that, calling enforcement disproportionate would be exactly the error I attack in others: an assertion without a denominator.

So I will say only what can be said: this case produces a sanction that looks larger than the drug, and that perception — right or wrong — will become a weapon for athletes who believe the system is against them. For an enforcement body, that is a real risk regardless of what the data eventually shows.

The other side matters more. Had she not forged the prescription, she had a real defence. Knee injury, injection, timing gap — documented properly, the presence charge could have been argued toward no-fault. The sanction might have been short, or the tampering charge might never have existed. In the best case, with a correct TUE and correct washout, there would have been no case at all.

So the real conclusion: the biggest enemy in this case was not the anti-doping agency. It was the advice she received — or did not receive.

What remains open

The AIU statement omits several things, and the omissions are themselves information.

There is no statement from the Ethiopian federation. That silence is a signal: the national body placed itself outside this case.

No investigation into an agent or management role is recorded. Whoever helped prepare or accepted that document is not named. Only the family member. The picture is incomplete.

A CAS appeal window is open — typically around 21 days from the reasoned decision. But a document-based finding is very hard to overturn. The risk exists; the probability of success is low.

And one thing nobody is saying: document forgery may also be a criminal matter. That sits outside AIU jurisdiction. Whether a referral to national authorities was made is unknown.

I do not chase the market; I audit the window until the pattern confesses. Here the window confessed, and the pattern is this: enforcement has shifted from substance to documentation, and the athletes who do not understand that their explanation will also be tested are receiving the heaviest sanctions.

Russia taught me this: the detour is not noise; it is the first honest signal. When I coded 412 javelin throws in 2026 and placed Neeraj Chopra's 86.47m on the distribution curve, the lesson was that a number without a distribution is an opinion wearing a lab coat. In Aga's case the distribution is this: hundreds of athletes across East African road running operate inside the same informal medical structure. Aga is a data point, not the edge of the distribution.

Takeaway

The AIU cases arriving over the next few months need a different reading method. Do not ask which substance was found. Ask whether the explanation could be verified. Where the answer is no, the size of the sanction will be set by the document, not the drug.

One thing is clear. A thirty-two-year-old who won a Major and finished second at three others will next stand on a start line at thirty-eight — if she stands at all. This sanction became the biggest event of her career, and it did not happen on a track.

Those who read this as a fraud story will learn nothing. Those who read it as a structural failure will have something to act on. The open question is whose responsibility that structure is — the federation's, the agent's, or the athlete's own. Until that is answered, the next prescription is already being written.